Terms: = Lymphoma AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
45 results:
1. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
2. Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative
Nazmy MH; Abu-Baih DH; Elrehany MA; Mustafa M; Aly OM; El-Sheikh AAK; Fathy M
Front Biosci (Landmark Ed); 2023 Aug; 28(8):185. PubMed ID: 37664933
[TBL] [Abstract] [Full Text] [Related]
3. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
Salaverria I; Weigert O; Quintanilla-Martinez L
Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
[TBL] [Abstract] [Full Text] [Related]
4. A kinase inhibitor screen reveals mek1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
[TBL] [Abstract] [Full Text] [Related]
5. [Rosai-Dorfman-Destombes disease with a misleading laryngeal presentation].
Fiani DJ; Émile JF; Istier L; Boutin AB; Tychyj C; Benzerdjeb N; Donzel M; Balme B; Traverse-Glehen A; Fontaine J
Ann Pathol; 2022 Nov; 42(6):475-480. PubMed ID: 36038429
[TBL] [Abstract] [Full Text] [Related]
6. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
[TBL] [Abstract] [Full Text] [Related]
7. Activation of mek1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell lymphoma.
Jia X; He Q; Zeng M; Chen Y; Liu Y
Anal Cell Pathol (Amst); 2021; 2021():6668947. PubMed ID: 34239803
[TBL] [Abstract] [Full Text] [Related]
8. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
9. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?
Matutes E
Expert Rev Hematol; 2021 Apr; 14(4):355-363. PubMed ID: 33759673
[TBL] [Abstract] [Full Text] [Related]
11. Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells.
Wang D; Shen M; Kitamura N; Sennari Y; Morita K; Tsukada J; Kanazawa T; Yoshida Y
Invest New Drugs; 2021 Feb; 39(1):122-130. PubMed ID: 32914311
[TBL] [Abstract] [Full Text] [Related]
12. MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.
Chen LZ; Ding Z; Zhang Y; He ST; Wang XH
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3734-3741. PubMed ID: 29949147
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
Crassini K; Pyke T; Shen Y; Stevenson WS; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2018 Dec; 59(12):2917-2928. PubMed ID: 29911936
[TBL] [Abstract] [Full Text] [Related]
14. Pan-class I PI3-kinase inhibitor BKM120 induces mek1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Müller A; Gillissen B; Richter A; Richter A; Chumduri C; Daniel PT; Scholz CW
Cell Death Dis; 2018 Mar; 9(3):384. PubMed ID: 29515122
[TBL] [Abstract] [Full Text] [Related]
15. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
[TBL] [Abstract] [Full Text] [Related]
16. Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Ding H; Peterson KL; Correia C; Koh B; Schneider PA; Nowakowski GS; Kaufmann SH
Leukemia; 2017 Jul; 31(7):1593-1602. PubMed ID: 27890930
[TBL] [Abstract] [Full Text] [Related]
17. S1PR1 mediates anti‑apoptotic/pro‑proliferative processes in human acute myeloid leukemia cells.
Xu XQ; Huang CM; Zhang YF; Chen L; Cheng H; Wang JM
Mol Med Rep; 2016 Oct; 14(4):3369-75. PubMed ID: 27572094
[TBL] [Abstract] [Full Text] [Related]
18. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.
Louissaint A; Schafernak KT; Geyer JT; Kovach AE; Ghandi M; Gratzinger D; Roth CG; Paxton CN; Kim S; Namgyal C; Morin R; Morgan EA; Neuberg DS; South ST; Harris MH; Hasserjian RP; Hochberg EP; Garraway LA; Harris NL; Weinstock DM
Blood; 2016 Aug; 128(8):1093-100. PubMed ID: 27325104
[TBL] [Abstract] [Full Text] [Related]
19. The role of the RAS pathway in iAMP21-ALL.
Ryan SL; Matheson E; Grossmann V; Sinclair P; Bashton M; Schwab C; Towers W; Partington M; Elliott A; Minto L; Richardson S; Rahman T; Keavney B; Skinner R; Bown N; Haferlach T; Vandenberghe P; Haferlach C; Santibanez-Koref M; Moorman AV; Kohlmann A; Irving JA; Harrison CJ
Leukemia; 2016 Sep; 30(9):1824-31. PubMed ID: 27168466
[TBL] [Abstract] [Full Text] [Related]
20. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Gao M; Chen G; Wang H; Xie B; Hu L; Kong Y; Yang G; Tao Y; Han Y; Wu X; Zhang Y; Dai B; Shi J
Oncotarget; 2016 May; 7(20):29102-15. PubMed ID: 27074555
[TBL] [Abstract] [Full Text] [Related]
[Next]
